… of the BRAF V600E mutation was significantly associated with increased cancer-related …
was not independent of tumor features, how to use BRAF V600E to manage mortality risk in …

… Influence of the BRAF V600E mutation on expression of vascular endothelial growth
factor in papillary thyroid cancer.Journal of Clinical Endocrinology and Metabolism 91 3667–3670. …

… on the American Joint Committee on Cancer staging system. Genomic DNA … BRAF V600E
mutation, as described in our previously published studies. In all cases, BRAF V600E mutation …

… (PTC) offers excellent prognosis, however relapse risk or persistent disease is related to…
BRAF V600E mutation is such a marker. Many studies analyzing the prevalence of the mutation …

… We aim to investigate the risk factors that may predict the BRAF V600E mutation potential of
… 9,908 papillary thyroid carcinoma patients with average 74.6% BRAF V600E mutations were …

… found in papillary thyroid cancer (PTC). Recent studies show that this mutation occurs more
… evaluate the prevalence of the BRAF V600E mutation in tumor samples and its association …

… presenting annually (seer.cancer.gov). The most common form of thyroid cancer is papillary
thyroid cancer (PTC), comprising 65–88% of all differentiated thyroid cancers (1). Although …

… Background: The BRAF V600E mutation is the most frequent genetic alteration in papillary
thyroid carcinoma (PTC). The role of BRAF V600E mutation as a poor prognostic factor has …

… BRAF V600E mutation, resulting from the BRAFT1799A transversion, is the most common
genetic mutation in papillary thyroid carcinoma (… function of the V600E mutation in controlling …

… the BRAF V600E mutation … BRAF V600E mutation with molecular markers and
clinicopathological parameters. After adjustments for age, sex, and tumor size, the BRAF V600E …